Oral Glucose Tolerance Test (OGTT): When to Order This Test

What the OGTT Actually Measures

The oral glucose tolerance test challenges the pancreas and peripheral tissues with a fixed glucose load, then tracks plasma glucose at timed intervals to reveal defects in insulin secretion or insulin sensitivity that a fasting glucose alone may miss. A fasting glucose of 105 mg/dL might look reassuring, yet the same patient could reach 185 mg/dL at two hours, deep inside the prediabetes range.

The test is not a single number. It is a glucose-clearance curve. That curve distinguishes normal glucose tolerance, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), and overt diabetes in both pregnant and non-pregnant populations.

The Physiology Behind the Curve

After swallowing the glucose solution, intestinal absorption begins within 10 to 15 minutes, driving blood glucose upward. A healthy beta cell responds with a first-phase insulin spike within 1 to 3 minutes of glucose sensing, followed by a sustained second phase. Peripheral muscle and adipose tissue then take up glucose under insulin stimulation. In type 2 diabetes or prediabetes, first-phase insulin secretion is blunted or absent, so the 1-hour value climbs higher and the 2-hour value stays elevated longer.

Insulin resistance shifts the entire curve upward without necessarily flattening it, which is why the 2-hour threshold catches cases that a peak-glucose measurement would miss.

Standardized Glucose Loads and Protocols

Two loads are in common clinical use:

• 75 g OGTT. The World Health Organization and American Diabetes Association (ADA) standard for non-pregnant adults and for the one-step gestational diabetes protocol. The patient drinks 75 g of anhydrous glucose in 250 to 300 mL water over 5 minutes. Blood is drawn at 0 (fasting), 1 hour, and 2 hours. The ADA 2024 Standards of Care define the diagnostic cut-points for this load.

• 100 g OGTT. Used in the two-step Carpenter-Coustan approach to gestational diabetes screening endorsed by ACOG. Blood is drawn at 0, 1, 2, and 3 hours after the patient drinks the 100 g load. At least two values must meet or exceed the threshold to establish gestational diabetes mellitus (GDM). ACOG Practice Bulletin 190 outlines both the Carpenter-Coustan and the National Diabetes Data Group cut-points.

Normal OGTT Ranges

Reference intervals differ by glucose load, time point, and whether the patient is pregnant. Using the wrong table is a common source of clinical error.

Non-Pregnant Adults: 75 g Protocol

The ADA 2024 Standards of Care apply the following thresholds for the 75 g OGTT in non-pregnant adults:

| Time Point | Normal | Prediabetes (IGT) | Diabetes | |---|---|---|---| | Fasting | <100 mg/dL | 100 to 125 mg/dL (IFG) | ≥126 mg/dL | | 1 hour | No established cut-point* |, |, | | 2 hours | <140 mg/dL | 140 to 199 mg/dL | ≥200 mg/dL |

*A 1-hour value ≥155 mg/dL has been proposed as a secondary risk marker in research settings but is not yet a standard diagnostic criterion in US guidelines.

Impaired fasting glucose (100 to 125 mg/dL) and impaired glucose tolerance (2-hour 140 to 199 mg/dL) are distinct physiological states that frequently coexist. The Diabetes Prevention Program (DPP, N=3,234) showed that patients with both IFG and IGT progressed to diabetes at roughly 11% per year without intervention, versus about 4 to 5% per year for either abnormality alone.

Gestational Diabetes: Two-Step 100 g Protocol

The Carpenter-Coustan cut-points for the 100 g, 3-hour OGTT require at least two abnormal values to diagnose GDM:

| Time Point | Carpenter-Coustan Threshold | |---|---| | Fasting | ≥95 mg/dL | | 1 hour | ≥180 mg/dL | | 2 hours | ≥155 mg/dL | | 3 hours | ≥140 mg/dL |

The National Diabetes Data Group (NDDG) thresholds (used by some centers) are slightly higher: 105/190/165/145 mg/dL. Each laboratory should specify which threshold set it applies, because choosing Carpenter-Coustan versus NDDG changes the GDM prevalence in a given cohort by approximately 50%.

Gestational Diabetes: One-Step 75 g Protocol

The International Association of Diabetes and Pregnancy Study Groups (IADPSG) 2010 consensus, adopted by the WHO, uses a single abnormal value on the 75 g OGTT:

| Time Point | GDM Threshold | |---|---| | Fasting | ≥92 mg/dL | | 1 hour | ≥180 mg/dL | | 2 hours | ≥153 mg/dL |

The HAPO Study (N=23,316) provided the epidemiological foundation for these cut-points by demonstrating continuous associations between maternal glucose and adverse perinatal outcomes across the full glucose distribution, with no identifiable threshold below which risk was absent.

When to Order the OGTT

Ordering decisions depend on the clinical question. The OGTT is not a first-line screening tool for most non-pregnant adults, that role belongs to fasting plasma glucose or HbA1c, but it becomes the preferred test in several specific situations.

Gestational Diabetes Screening

The OGTT is the definitive test for GDM. ACOG Practice Bulletin 190 recommends universal screening between 24 and 28 weeks of gestation, regardless of pre-pregnancy BMI or prior history.

Patients at high risk for pre-existing type 2 diabetes should be screened at the first prenatal visit using standard non-pregnant criteria (fasting glucose, HbA1c, or random glucose). If those results are normal, repeat GDM screening still occurs at 24 to 28 weeks using the OGTT. Risk factors that trigger early screening include:

• BMI ≥30 kg/m²
• Previous GDM in a prior pregnancy
• Prior delivery of an infant weighing >4,000 g (macrosomia)
• First-degree relative with type 2 diabetes
• Polycystic ovary syndrome (PCOS)
• Ethnicity with elevated diabetes prevalence (South Asian, Hispanic, African American, Native American, Pacific Islander)

The U.S. Preventive Services Task Force (USPSTF) 2021 recommendation assigns a Grade B to GDM screening in asymptomatic pregnant persons at 24 weeks or later, confirming that the benefit-harm balance favors universal testing.

Prediabetes and Type 2 Diabetes Confirmation

Fasting glucose and HbA1c miss a subset of patients whose primary defect is postprandial hyperglycemia. The ADA 2024 Standards state: "The 2-hour plasma glucose value during a 75-g OGTT is a better predictor of cardiovascular risk than fasting plasma glucose and HbA1c in people with impaired glucose tolerance."

Order a 75 g OGTT for non-pregnant adults in these situations:

• Fasting glucose consistently 100 to 125 mg/dL (IFG) with a normal or borderline HbA1c, to determine whether postprandial clearance is also impaired.
• HbA1c 5.7 to 6.4% but the clinician suspects the A1c underestimates true glycemia (hemoglobinopathy, iron-deficiency anemia, recent blood transfusion, chronic kidney disease).
• Unexplained symptoms of hyperglycemia (polyuria, polydipsia, blurred vision) with a non-diagnostic fasting glucose.
• Evaluation of a patient at high cardiovascular risk where IGT, not just IFG, affects treatment decisions, such as whether to initiate a GLP-1 receptor agonist or intensive lifestyle intervention.

The Endocrine Society Clinical Practice Guideline on Type 2 Diabetes Prevention recommends that adults with IFG undergo OGTT if additional risk stratification would change management, particularly when considering pharmacotherapy with metformin.

Reactive Hypoglycemia Evaluation

Patients reporting shakiness, diaphoresis, palpitations, or cognitive impairment 2 to 4 hours after meals may have postprandial (reactive) hypoglycemia. A 75 g OGTT extended to 4 to 5 hours, with glucose and insulin measured at each time point, characterizes the glucose nadir and whether hypoglycemia is accompanied by insulin excess (suggesting insulinoma or functional hyperinsulinism) or occurs with normal insulin (suggesting accelerated gastric emptying or post-bariatric physiology).

The Endocrine Society's 2009 guideline on hypoglycemia notes that a 5-hour OGTT is acceptable for confirming postprandial hypoglycemia when a mixed-meal test is not available, provided a plasma glucose <55 mg/dL is documented during symptoms (Whipple's triad criterion).

Post-Bariatric Surgery Monitoring

Roux-en-Y gastric bypass and sleeve gastrectomy alter gastric emptying and incretin dynamics so profoundly that fasting glucose and HbA1c frequently underestimate postprandial excursions. Some bariatric centers use a liquid mixed-meal tolerance test instead of the standard OGTT, but a modified 75 g OGTT with additional time points at 30 and 60 minutes provides clinically useful data on dumping physiology and late hypoglycemia.

Polycystic Ovary Syndrome (PCOS)

The Endocrine Society 2023 PCOS Guideline recommends an OGTT at diagnosis and every 3 to 5 years thereafter for patients with PCOS, regardless of BMI, because insulin resistance in PCOS produces postprandial hyperglycemia that may not be captured by fasting glucose alone. PCOS affects approximately 10% of reproductive-age women and carries a 4-fold elevated lifetime risk of type 2 diabetes compared to the general population.

How to Prepare for the OGTT

Patient preparation is not optional. Poor preparation produces false-positive and false-negative results.

Pre-Test Dietary and Activity Requirements

• Consume at least 150 g of carbohydrate per day for 3 days before the test. Carbohydrate restriction in the days prior blunts insulin sensitivity adaptations and artificially elevates post-load glucose.
• Fast for 8 to 14 hours before the blood draw. Water is permitted. Coffee, tea, and other beverages are not permitted.
• Avoid strenuous exercise for 24 hours before the test; exercise acutely improves insulin sensitivity and may produce a false-negative result in a patient with early glucose intolerance.
• Do not smoke on the morning of the test. Nicotine raises plasma catecholamines and elevates glucose.

During the Test

The patient must remain seated and at rest throughout the test. Walking to the bathroom briefly is acceptable; any sustained physical activity invalidates the result. Vomiting during the test requires rescheduling. Some laboratories allow the test to continue if the patient vomits more than 30 minutes after ingesting the glucose solution, but institutional protocols vary.

Medications That Affect Results

Corticosteroids, antipsychotics (particularly olanzapine and clozapine), thiazide diuretics, and niacin can raise the 2-hour glucose. Beta-blockers may blunt the symptomatic response to hypoglycemia during an extended test but do not systematically alter glucose values. Metformin and GLP-1 receptor agonists should ideally be withheld for 24 to 48 hours if the clinical question is diagnostic rather than therapeutic monitoring, discuss with the ordering physician before stopping any medication.

What High OGTT Values Mean

Confirming Type 2 Diabetes

A single 2-hour glucose ≥200 mg/dL on the 75 g OGTT, in a patient with classic symptoms, is sufficient to diagnose diabetes per the ADA 2024 Standards. In an asymptomatic patient, a second confirmatory test on a different day is required unless two separate tests from the same blood draw are both abnormal.

The UKPDS (N=5,102) remains the landmark trial establishing that newly diagnosed type 2 diabetes patients have already lost approximately 50% of beta-cell function at diagnosis, underscoring why early detection through OGTT matters.

Impaired Glucose Tolerance and Cardiovascular Risk

A 2-hour value of 140 to 199 mg/dL denotes IGT. The DECODE Study (N=22,514) demonstrated that the 2-hour post-load glucose predicted all-cause and cardiovascular mortality independently of fasting glucose, with a hazard ratio of 1.73 (95% CI 1.45 to 2.06) for the highest 2-hour glucose quintile after adjustment for fasting glucose. This finding is why cardiologists and endocrinologists sometimes request an OGTT for risk stratification even when the fasting glucose is normal.

Gestational Diabetes and Perinatal Outcomes

Meeting GDM criteria triggers a management pathway that significantly reduces adverse outcomes. The ACHOIS trial (N=1,000) showed that treating GDM (diet, monitoring, insulin when needed) reduced a composite of serious perinatal complications from 4% to 1% compared with routine care (P<0.01). Untreated GDM is associated with macrosomia, shoulder dystocia, neonatal hypoglycemia, and a higher risk of cesarean delivery.

What Low OGTT Values Mean

A 2-hour value below 70 mg/dL during a standard OGTT is uncommon in healthy adults and may indicate:

• Functional or reactive hypoglycemia, particularly if symptoms coincide with the glucose nadir.
• Insulinoma (rare), especially if the fasting glucose at time zero is also low and insulin levels are inappropriately elevated at the nadir.
• Post-gastric-bypass physiology with rapid glucose absorption followed by excessive incretin-mediated insulin secretion (late dumping syndrome).

The Endocrine Society 2022 Endogenous Hyperinsulinism Guideline notes that a prolonged supervised fast (72-hour fast) is preferred over the OGTT for diagnosing insulinoma, because the OGTT can cause paradoxical hypoglycemia in normal individuals and lacks specificity for the diagnosis.

How to Lower an Abnormal OGTT

When OGTT results fall in the prediabetes or GDM range, the goal is to reduce postprandial glucose excursions and improve insulin sensitivity before overt diabetes develops.

Lifestyle Interventions With Proven Efficacy

The DPP N=3,234, NEJM 2002 showed that an intensive lifestyle program (7% body weight loss, 150 minutes per week of moderate-intensity activity) reduced progression from IGT to diabetes by 58% over 2.8 years, compared with 31% for metformin 850 mg twice daily and 0% for placebo. The lifestyle benefit was greater in patients over 60 years old (71% risk reduction).

Specific dietary changes that reduce 2-hour OGTT values include:

• Replacing refined grains with non-starchy vegetables and legumes to slow gastric emptying.
• Consuming protein and fat before carbohydrates at a meal (food order effect), which reduces postprandial glucose by approximately 29% in patients with type 2 diabetes per Shukla et al., Diabetes Care 2017.
• Reducing total carbohydrate load per meal rather than per day, since the OGTT is measuring a single-meal excursion.

Post-meal walking (10 minutes at a moderate pace) after each major meal reduces 3-hour glucose area under the curve by approximately 12% compared with a single 30-minute continuous walk, per Colberg et al., Diabetes Care 2013.

Pharmacologic Options

For non-pregnant adults with IGT who meet DPP criteria, metformin 850 to 1,000 mg twice daily is the only medication with a Grade B USPSTF recommendation for diabetes prevention. GLP-1 receptor agonists (liraglutide, semaglutide) have shown significant reductions in progression from prediabetes to diabetes in post-hoc analyses of SCALE and STEP trials, though primary prevention labeling has not been granted. The FDA label for semaglutide 2.4 mg (Wegovy) is currently for chronic weight management, not diabetes prevention specifically.

For GDM, insulin is the first-line pharmacologic agent when diet and exercise fail to achieve targets (fasting <95 mg/dL, 1-hour post-meal <140 mg/dL, 2-hour post-meal <120 mg/dL). Metformin and glyburide are used off-label in GDM; metformin crosses the placenta and ACOG Practice Bulletin 190 states that while it is an acceptable alternative, long-term neonatal safety data beyond age 9 are limited.

The HealthRX clinical decision framework below summarizes when to use the OGTT versus fasting glucose versus HbA1c across four patient scenarios. During editorial review, the medical team will insert a custom illustration of this framework.

Framework: Choosing Between OGTT, Fasting Glucose, and HbA1c

| Clinical Scenario | Preferred Initial Test | When to Add OGTT | |---|---|---| | Routine diabetes screening, non-pregnant adult, no known risk factors | Fasting plasma glucose or HbA1c | If IFG 100 to 125 or HbA1c 5.7 to 6.4% and clinical decisions hinge on IGT status | | Pregnancy, 24 to 28 weeks | 1-hour 50 g glucose challenge screen (two-step) OR 75 g OGTT direct (one-step) | Two-step: if screen ≥130 to 140 mg/dL, proceed to 100 g OGTT | | Suspected reactive hypoglycemia | Extended 75 g OGTT with 4-hour glucose and insulin | Always; fasting glucose and HbA1c cannot diagnose this condition | | PCOS at diagnosis | 75 g OGTT | Every 3 to 5 years regardless of prior results |

Postpartum Testing After GDM

GDM resolves after delivery in most patients, but the underlying insulin resistance often does not. Women with a history of GDM have a 50% lifetime risk of developing type 2 diabetes per Bellamy et al., Lancet 2009 (N=675,455).

The ADA 2024 Standards recommend a 75 g OGTT at 4 to 12 weeks postpartum (not HbA1c, which is unreliable during the postpartum period due to recent blood loss and hemodilution). Thereafter, testing should occur every 1 to 3 years using any validated method.

Only 19 to 37% of women with GDM receive postpartum glucose testing in the U.S. Despite these guidelines, a gap that represents one of the most actionable missed opportunities in preventive endocrinology.